Latest News:
ardeelenfrit
Home » Author Archives: tifwp

Author Archives: tifwp

Alpha thalassaemia

This section is dedicated to alpha (α-) thalassaemia. THE MAJOR ALPHA (α-) THALASSAEMIAS ARE: HbH disease α-thalassaemia Hydrops Foetalis (=Hb Bart’s Hydrops Foetalis) Many diseases in humans are caused by abnormalities in the blood and these are categorized according to the component of the blood which is affected: white cell ...

Read More »

Patients for Patient Safety – Spring 2017

Patients’ stories of health care harm touch people’s hearts. The stories of the experiences of how patients and families can and do turn tragedy into compassion and motivation for change inspire people and help to raise awareness of the need to improve patient safety and health care quality.

Read More »

Clinical trial update (April 2017)

Important Note: The latest Clinical Trial updates can be found in the link below.   April 2017 update Luspatercept (ACE-536): A novel agent that increases haemoglobin by promoting erythropoiesis (differentiation and maturation of late-stage erythrocyte precursors). Phase 2 data in adults with β-thalassaemia shows sustained increase in haemoglobin levels with ...

Read More »

‘Prize for Outstanding Patient’s Contribution to TIF’s Activities’

As from 2016, Thalassemia International Federation (TIF) has established a new kind of Award to be included in TIF’s Awards Scheme the ‘Prize for Outstanding Patient’s Contribution to TIF’s Activities’. This Prize will be awarded on a biannual basis in the context of a  General Assembly or an International Conference ...

Read More »